Try a new search

Format these results:

Searched for:

in-biosketch:true

person:lischj02

Total Results:

96


Secondary Malignancy Risk Following Proton vs. X-ray Treatment of Mediastinal Malignant Lymphoma: A Comparative Modeling Study of Thoracic Organ-Specific Cancer Risk

Koenig, Laila; Haering, Peter; Lang, Clemens; Splinter, Mona; von Nettelbladt, Bastian; Weykamp, Fabian; Hoegen, Philipp; Lischalk, Jonathan W.; Herfarth, Klaus; Debus, Juergen; Hoerner-Rieber, Juliane
ISI:000553369500001
ISSN: 2234-943x
CID: 5013562

Ten-Year Single Institutional Analysis of Geographic and Demographic Characteristics of Patients Treated With Stereotactic Body Radiation Therapy for Localized Prostate Cancer

Aghdam, Nima; Carrasquilla, Michael; Wang, Edina; Pepin, Abigail N; Danner, Malika; Ayoob, Marilyn; Yung, Thomas; Collins, Brian T; Kumar, Deepak; Suy, Simeng; Collins, Sean P; Lischalk, Jonathan W
Objectives/UNASSIGNED:Stereotactic Body Radiation Therapy (SBRT) offers definitive treatment for localized prostate cancer with comparable efficacy and toxicity to conventionally fractionated radiotherapy. Decreasing the number of treatment visits from over 40 to five may ease treatment burden and increase accessibility for logistically challenged patients. Travel distance is one factor that affects a patient's access to treatment and is often related to geographic location and socioeconomic status. In this study, we review the demographic and geographic factors of patients treated with SBRT for prostate cancer for a single institution with over a decade of experience. Methods/UNASSIGNED:Patient zip codes from one thousand and thirty-five patients were derived from a large, prospectively maintained quality of life database for patients treated for prostate cancer with SBRT from 2008 to 2017. The geospatial distance between the centroid of each zip code to our institution was calculated using the R package Geosphere. Characteristics for seven hundred and twenty-one patients were evaluated at the time of analysis including: race, age, and insurance status. To assess the geographic reach of our institution, we evaluated the demographic features of each zip code using US Census data. Statistical comparisons for these features and their relation to distance traveled for treatment was performed using the Mann-Whitney U test. Finally, an unsupervised learning algorithm was performed to identify distinct clusters of patients with respect to median income, racial makeup, educational level, and rural residency. Results/UNASSIGNED:Patients traveled from 246 distinct zip codes at a median distance of 11.35 miles. Forty percent of patients were African American, 6.9% resided in a rural region, and 22% were over the age of 75. Using K-means cluster analysis, four distinct patient zip-code groups were identified based on the aforementioned demographic features: Suburban/high-income (45%), Urban (30%), Suburban/low-income (17%), and Rural (8%). For each of the clusters, the average travel distance for SBRT was significantly different at 11.17, 9.26, 11.75, and 40.2 miles, respectively (p-value: <0.001). Conclusions/UNASSIGNED:Distinct demographic features are related to travel distance for prostate SBRT. In our large cohort, travel distance did not prevent uptake of prostate SBRT in African American, elderly or rural patient populations. Prostate SBRT offers a diverse population modern treatment for their localized prostate cancer and particularly for those who live significant distances from a treatment center.
PMCID:7947279
PMID: 33718117
ISSN: 2234-943x
CID: 5013482

Management of Isolated Local Failures Following Stereotactic Body Radiation Therapy for Low to Intermediate Risk Prostate Cancer

Aghdam, Nima; Pepin, Abigail N; Creswell, Michael; Hsieh, Kristin; Smith, Clayton; Drescher, Nicolette; Danner, Malika; Ayoob, Marilyn; Yung, Thomas; Lei, Siyuan; Kumar, Deepak; Collins, Brian Timothy; Lischalk, Jonathan W; Krishnan, Pranay; Suy, Simeng; Lynch, John; Bandi, Guarav; Hankins, Ryan Andrew; Collins, Sean P
PMCID:7673419
PMID: 33251131
ISSN: 2234-943x
CID: 5013412

Arteriovenous Malformations Treated With Frameless Robotic Radiosurgery Using Non-Invasive Angiography: Long-Term Outcomes of a Single Center Pilot Study

Kelly, Ryan; Conte, Anthony; Nair, M Nathan; Voyadzis, Jean-Marc; Anaizi, Amjad; Collins, Sean; Kalhorn, Christopher; Stemer, Andrew; Mai, Jeffery; Armonda, Rocco; Lischalk, Jonathan; Berkowitz, Frank; Nayar, Vikram; McGrail, Kevin; Collins, Brian Timothy
Objective/UNASSIGNED:CT-guided, frameless robotic radiosurgery is a novel radiotherapy technique for the treatment of intracranial arteriovenous malformations (AVMs) that serves as an alternative to traditional catheter-angiography targeted, frame-based methods. Methods/UNASSIGNED:Patients diagnosed with AVMs who completed single fraction frameless robotic radiosurgery at Medstar Georgetown University Hospital between July 20, 2006 - March 11, 2013 were included in the present study. All patients received pre-treatment planning with CT angiogram (CTA) and MRI, and were treated using the CyberKnife radiosurgery platform. Patients were followed for at least four years or until radiographic obliteration of the AVM was observed. Results/UNASSIGNED:Twenty patients were included in the present study. The majority of patients were diagnosed with Spetzler Martin Grade II (35%) or III (35%) AVMs. The AVM median nidus diameter and nidal volume was 1.8 cm and 4.38 cc, respectively. Median stereotactic radiosurgery dose was 1,800 cGy. After a median follow-up of 42 months, the majority of patients (81.3%) had complete obliteration of their AVM. All patients who were treated to a total dose of 1800 cGy demonstrated complete obliteration. One patient treated at a dose of 2,200 cGy developed temporary treatment-related toxicity, and one patient developed post-treatment hemorrhage. Conclusions/UNASSIGNED:Frameless robotic radiosurgery with non-invasive CTA and MRI radiography appears to be a safe and effective radiation modality and serves as a novel alternative to traditional invasive catheter-angiography, frame-based methods for the treatment of intracranial AVMs. Adequate obliteration can be achieved utilizing 1,800 cGy in a single fraction, and minimizes treatment-related side effects.
PMCID:7734323
PMID: 33330045
ISSN: 2234-943x
CID: 5013432

Secondary Malignancy Risk Following Proton vs. X-ray Treatment of Mediastinal Malignant Lymphoma: A Comparative Modeling Study of Thoracic Organ-Specific Cancer Risk

König, Laila; Haering, Peter; Lang, Clemens; Splinter, Mona; von Nettelbladt, Bastian; Weykamp, Fabian; Hoegen, Philipp; Lischalk, Jonathan W; Herfarth, Klaus; Debus, Jürgen; Hörner-Rieber, Juliane
PMCID:7358352
PMID: 32733794
ISSN: 2234-943x
CID: 5013392

Abscopal effect in pulmonary carcinoid tumor following ablative stereotactic body radiation therapy: a case report [Case Report]

Kareff, Samuel A; Lischalk, Jonathan W; Krochmal, Rebecca; Kim, Chul
BACKGROUND:The abscopal effect was described as early as the 1950s, when untreated tumors demonstrated a response after radiation therapy was delivered to an untreated, distant site. The mechanisms underlying this global response to otherwise localized therapy remain unknown, though there is increasing evidence that increased antigen expression following ablative radiotherapy may play a role. CASE PRESENTATION/METHODS:We report a case of a 69-year-old African American woman with a history of metastatic typical pulmonary carcinoid with multiple lung nodules who had a significant decrease in size of an untreated left upper lobe nodule after stereotactic body radiation therapy to an oligoprogressive left lower lobe lesion. CONCLUSIONS:To our knowledge, this report describes the first case of an abscopal effect in a typical pulmonary carcinoid. Further research is needed regarding the mechanisms responsible for this finding and the role of combining radiation therapy and cancer immunotherapy in patients with pulmonary carcinoid tumors.
PMCID:7532944
PMID: 33010806
ISSN: 1752-1947
CID: 5013402

Early Experience of the First Single-Room Gantry Mounted Active Scanning Proton Therapy System at an Integrated Cancer Center

Forsthoefel, Matthew K; Ballew, Elizabeth; Unger, Keith R; Ahn, Peter H; Rudra, Sonali; Pang, Dalong; Collins, Sean P; Dritschilo, Anatoly; Harter, William; Paudel, Nitika; Collins, Brian T; Lischalk, Jonathan W
PMCID:7273355
PMID: 32547953
ISSN: 2234-943x
CID: 5013382

Rationale for Involved Field Stereotactic Body Radiation Therapy-Enhanced Intermittent Androgen Deprivation Therapy in Hormone-Sensitive Nodal Oligo-Recurrent Prostate Cancer Following Prostate Stereotactic Body Radiation Therapy

Carrasquilla, Michael; Creswell, Michael L; Pepin, Abigail N; Wang, Edina; Forsthoefel, Matthew; McGunigal, Mary; Bullock, Elizabeth; Lei, Siyuan; Collins, Brian T; Lischalk, Jonathan W; Esposito, Giuseppe; Aghdam, Nima; Kumar, Deepak; Suy, Simeng; Leger, Paul; Hankins, Ryan A; Dawson, Nancy A; Collins, Sean P
Lymph node recurrent prostate cancer is a common clinical scenario that is likely to increase significantly with the widespread adoption of novel positron emission tomography (PET) agents. Despite increasing evidence that localized therapy is disease modifying, most men with lymph node recurrent prostate cancer receive only systemic therapy with androgen deprivation therapy (ADT). For men who receive localized therapy the intent is often to delay receipt of systemic therapy. Little evidence exists on the optimal combination of local and systemic therapy in this patient population. In this hypothesis generating review, we will outline the rationale and propose a framework for combining involved field SBRT with risk adapted intermittent ADT for hormone sensitive nodal recurrent prostate cancer. In patients with a limited number of nodal metastases, involved field stereotactic body radiation therapy (SBRT) may have a role in eliminating castrate-resistant clones and possibly prolonging the response to intermittent ADT. We hypothesize that in a small percentage of patients, such a treatment approach may lead to long term remission or cure.
PMCID:7848164
PMID: 33537236
ISSN: 2234-943x
CID: 5013452

Pediatric Intracranial Germinomas

Chapter by: Lischalk, Jonathan W.; MacDonald, Shannon M.
in: TARGET VOLUME DELINEATION FOR PEDIATRIC CANCERS by Terezakis, SA; MacDonald, SM (Eds)
pp. 55-70
ISBN: 978-3-319-69140-4
CID: 5014382

Clinical Efficacy of Frameless Stereotactic Radiosurgery in the Management of Spinal Metastases From Thyroid Carcinoma

Hariri, Omid; Takayanagi, Ariel; Lischalk, Jonathan; Desai, Kaniksha; Florence, Timothy J; Yazdian, Pouria; Chang, Steven D; Vrionis, Frank; Adler, John R; Quadri, Syed A; Desai, Atman
STUDY DESIGN/METHODS:A retrospective data review. OBJECTIVE:To evaluate the efficacy of CyberKnife (CK) stereotactic radiosurgery (SRS) for thyroid spinal metastasis (SMs). SUMMARY OF BACKGROUND DATA/BACKGROUND:Thyroid carcinoma is an infrequent cause of SM. The absolute efficacy of SRS generally and CK in particular remains poorly characterized for thyroid SM. The current study is the first to specifically evaluate the efficacy of CK SRS for thyroid SMs. METHODS:A retrospective review of patients at our institution between 2003 and 2013 was done. Details about tumor location, radiographic findings before and after CK SRS, tumor recurrence, prescription isodose level, total and maximum dose, number of fractions, and gross tumor volume coverage were similarly collected. For comparison with other studies, the biologically effective dose and the equivalent total dose in 2 Gy fractions were calculated. Each patient was assessed for survival and local disease control from the time of the first CK session and survival analysis was carried out using the Kaplan-Meier method. Risk factors for local failure were assessed using multivariate logistic regression. RESULTS:A total of 12 patients with 32 spinal metastases from thyroid carcinoma that were treated with CK SRS were identified. Survival for 1, 2, and 3 years was 55%, 44%, and 33%, and local control was 67%, 56%, and 34% respectively. The study found that the single strongest factor associated with local control was prior radiotherapy (β-coefficient -27.72, P = 0.01). No complications occurred in the immediate or late follow-up period. CONCLUSION/CONCLUSIONS:This was the first study to specifically investigate the efficacy of CK for treatment of thyroid SMs. Our findings suggest that CK can be safely used to treat spinal SMs from thyroid cancer and is associated with a high rate of local control. LEVEL OF EVIDENCE/METHODS:4.
PMID: 31261273
ISSN: 1528-1159
CID: 5013372